Matches in Wikidata for { <http://www.wikidata.org/entity/Q88632396> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q88632396 description "article scientifique publié en 2018" @default.
- Q88632396 description "artículu científicu espublizáu en marzu de 2018" @default.
- Q88632396 description "scientific article published on 17 March 2018" @default.
- Q88632396 description "wetenschappelijk artikel" @default.
- Q88632396 description "наукова стаття, опублікована 17 березня 2018" @default.
- Q88632396 name "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 name "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 type Item @default.
- Q88632396 label "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 label "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 prefLabel "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 prefLabel "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 P1433 Q88632396-F2DB8AD9-6D70-4FD0-988B-F2EAA53763C2 @default.
- Q88632396 P1476 Q88632396-3000B418-6B47-4E00-9A5C-C001CEA461F4 @default.
- Q88632396 P2093 Q88632396-14CBB291-DA35-4C48-953E-95C98F7337B1 @default.
- Q88632396 P2093 Q88632396-2C253CEA-E74D-46B4-B750-45F843308935 @default.
- Q88632396 P2093 Q88632396-333C7F4D-3154-4B4E-8E1C-FCDD7265B0E3 @default.
- Q88632396 P2093 Q88632396-3DE338D3-5DD9-44D3-9394-B79E6271450E @default.
- Q88632396 P2093 Q88632396-41E11219-4F90-4B9C-8AD9-4F1071DAF6A4 @default.
- Q88632396 P2093 Q88632396-45FB5323-6233-42BF-9156-84DFCD58AF13 @default.
- Q88632396 P2093 Q88632396-650F04F5-D286-4D7B-B5DA-A17EB4919EF2 @default.
- Q88632396 P2093 Q88632396-65D47E4C-4ABC-43B2-ACAE-B2B7D6643DFA @default.
- Q88632396 P2093 Q88632396-802701B9-07AE-42D2-9E9A-62528824FED5 @default.
- Q88632396 P2093 Q88632396-B2024263-368B-44DD-A685-559164D83F6C @default.
- Q88632396 P2093 Q88632396-B4AA267E-B85D-44AC-8574-2DA86457F469 @default.
- Q88632396 P2093 Q88632396-B6A0B0EA-196F-4715-BD5B-A1B42EDE8BE7 @default.
- Q88632396 P304 Q88632396-C12E16ED-1169-43D3-BCEE-E1E363B81D8D @default.
- Q88632396 P31 Q88632396-A3E6C133-6D47-4D04-A7C3-A5C6FA790E77 @default.
- Q88632396 P356 Q88632396-7FE7CE9D-FDDE-49D1-BF02-37CA9D177CE9 @default.
- Q88632396 P478 Q88632396-3F27E640-6005-4339-B74A-AB40EE6B2BBA @default.
- Q88632396 P577 Q88632396-658DF42D-1D88-4828-8005-09802B0B7D75 @default.
- Q88632396 P698 Q88632396-C59EFC38-64EC-4871-98A9-0D7F2C73D277 @default.
- Q88632396 P921 Q88632396-C737ADFF-05E0-4528-8F28-5C596643D412 @default.
- Q88632396 P921 Q88632396-EBCD5A93-B837-47C2-8110-E56AF1822234 @default.
- Q88632396 P356 J.LUNGCAN.2018.03.015 @default.
- Q88632396 P698 29748014 @default.
- Q88632396 P1433 Q641464 @default.
- Q88632396 P1476 "The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)" @default.
- Q88632396 P2093 "Achim Escherich" @default.
- Q88632396 P2093 "Arne Warth" @default.
- Q88632396 P2093 "Birgit Wehnl" @default.
- Q88632396 P2093 "Christa Stolp" @default.
- Q88632396 P2093 "Farshid Dayyani" @default.
- Q88632396 P2093 "Felix J Herth" @default.
- Q88632396 P2093 "Hendrik Dienemann" @default.
- Q88632396 P2093 "Marc A Schneider" @default.
- Q88632396 P2093 "Michael Meister" @default.
- Q88632396 P2093 "Thomas Muley" @default.
- Q88632396 P2093 "Vinzent Rolny" @default.
- Q88632396 P2093 "Ying He" @default.
- Q88632396 P304 "46-53" @default.
- Q88632396 P31 Q13442814 @default.
- Q88632396 P356 "10.1016/J.LUNGCAN.2018.03.015" @default.
- Q88632396 P478 "120" @default.
- Q88632396 P577 "2018-03-17T00:00:00Z" @default.
- Q88632396 P698 "29748014" @default.
- Q88632396 P921 Q5749020 @default.
- Q88632396 P921 Q864574 @default.